Validation and Refinement of the European LeukemiaNet 2022 Genetic Risk Stratification of AML
We conclude that ELN22 is prognostically valid in intensively treated younger patients with AML. Incorporation of <i>WT1</i> mutation status, triple-mutated <i>NPM1</i>, and LSC burden may improve risk stratification, particularly within the heterogeneous intermediate-risk category.
Authors
- Prasanna Bhanshe
- Nishant Jindal (ORCID: https://orcid.org/0000-0002-1423-1163)
- Lingaraj Nayak (ORCID: https://orcid.org/0000-0001-9520-795X)
- Shadma Shahin
- Bhausaheb Bagal (ORCID: https://orcid.org/0000-0001-9754-0182)
- Anant Gokarn (ORCID: https://orcid.org/0000-0002-8725-8375)
- Gojiri Mawalankar
- Aarti Ramesh Achrekar
- Vishram Terse
- Nikhil Patkar (ORCID: https://orcid.org/0009-0004-5993-5051)
- Swapnali Joshi
- Shruti Chaudhary
- Priyanka Rajesh Ugale
- Sarani Biswas (ORCID: https://orcid.org/0009-0006-9378-3930)
- Saurabh Kusurkar
- Vaibhav Gawde
- Sweta Rajpal
- Gaurav Chatterjee
- Papagudi G Subramanian
- Hasmukh Jain
- Alok Shetty
- Manju Sengar
- Sumeet Mirgh
- Prashant Tembhare
- Sachin Punatar
- Dhanlaxmi Shetty
- Navin Khattry
Institutions
- Homi Bhabha National Institute (IN)
- Tata Memorial Hospital (IN)
- Advanced Centre for Treatment, Research and Education in Cancer (IN)
Publication Details
- Journal
- JCO Global Oncology
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1200/go-25-00443
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00